Vis enkel innførsel

dc.contributor.authorRognstad, Stine
dc.contributor.authorSøraas, Camilla Lund
dc.contributor.authorBergland, Ola Undrum
dc.contributor.authorHøieggen, Aud
dc.contributor.authorStrømmen, Magnus
dc.contributor.authorHelland, Arne
dc.contributor.authorOpdal, Mimi Stokke
dc.date.accessioned2021-09-27T07:24:02Z
dc.date.available2021-09-27T07:24:02Z
dc.date.created2021-01-05T12:48:52Z
dc.date.issued2020
dc.identifier.citationTherapeutic Drug Monitoring. 2020, 43 (1), 116-125.en_US
dc.identifier.issn0163-4356
dc.identifier.urihttps://hdl.handle.net/11250/2783588
dc.description.abstractBackground: Therapeutic drug monitoring (TDM) involves the measurement of serum drug concentrations to optimize pharmacotherapy. Traditionally, blood pressure measurements alone, and not TDM, have been used to evaluate the antihypertensive drug response. However, approximately 50% of hypertensive patients treated with lifestyle changes and antihypertensive drugs fail to achieve blood pressure control. Serum drug concentration measurements could be useful to select the optimal drugs in adjusted doses and to identify nonadherence. Implementation of TDM in clinical routine for antihypertensive drugs depends on established serum reference ranges. Methods: Commonly used antihypertensive drugs were identified based on prescription data. The authors performed a review of authoritative literature on reported serum drug concentrations and calculated expected concentrations from previously reported pharmacokinetic parameters with commonly prescribed daily doses. Finally, serum drug concentrations in samples from patients undergoing antihypertensive treatment were measured. Results: Serum reference ranges for 24 frequently used antihypertensive drugs were established based on results from 3 approaches. Conclusions: Serum drug concentration measurements, interpreted in light of the established reference ranges, together with blood pressure measurements and other clinical data, may help identify nonadherent patients and tailor individual antihypertensive treatment when deviant drug responses appear in line with the concept of personalized medicine.en_US
dc.language.isoengen_US
dc.publisherLippincott, Williams & Wilkinsen_US
dc.titleEstablishing Serum Reference Ranges for Antihypertensive Drugsen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionacceptedVersionen_US
dc.rights.holderThis is the authors' accepted manuscript to an article published by Lippincott, Williams & Wilkins. Locked until 28.2.2022 due to copyright restrictions.en_US
dc.source.pagenumber116-125en_US
dc.source.volume43en_US
dc.source.journalTherapeutic Drug Monitoringen_US
dc.source.issue1en_US
dc.identifier.doi10.1097/FTD.0000000000000806
dc.identifier.cristin1865531
cristin.ispublishedtrue
cristin.fulltextpostprint
cristin.qualitycode2


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel